RADNOR, Pa., Dec. 6, 2011 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTC BB:PYMX), a clinical-stage biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, is pleased to announce the launch of its redesigned company website at www.polymedix.com. The enhanced site captures the Company’s mission to develop innovative and cost-effective drug therapies for life-threatening acute conditions where there is a significant unmet medical need. Additionally, there is extensive information on PolyMedix’s two lead products, which are currently being evaluated in Phase 2 clinical studies.
